anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Each subject will participate in the trial from the time the subject signs the Informed Consent Form (ICF) through the final contact. After a screening phase of up to 28 days, eligible subjects will receive treatment beginning on Day 1 of each 2-week dosing cycle for aveluumab. Treatment with aveluumab will continue until documented disease progression, unacceptable adverse event(s),intercurrent illness that prevents further administration of treatment, Investigator's decision to withdraw the subject, subject withdraws consent, pregnancy of the subject, noncompliance with trial treatment or procedure requirements, After the end of treatment, each subject will be followed for 30 days for adverse event monitoring (serious adverse events and events of clinical interest will be collected for 90 days after the end of treatment or 30 days after the end of treatment if the subject initiates new anticancer therapy, whichever is earlier). Subjects who discontinue after 24months of therapy for reasons other than disease progression or intolerability or who discontinue after attaining a CR may be eligible for up to one year of retreatment after they have experienced radiographic disease progression. Subjects who discontinue for reasons other than disease progression will have post-treatment follow-up for disease status until disease progression, initiating a non-study cancer treatment, withdrawing consent, or becoming lost to follow-up. All subjects will be followed by telephone for overall survival until death, withdrawal of consent, or the end of the study.
Cohorts of 3-6 patients in each genotype group will receive escalating doses of capecitabine until MTD is reached. Once MTD is determined, an additional 6-9 patients (for a total of 12 patients) will receive treatment at that dose.
The invention provides an anti-inflammation and detoxification preparation. The preparation mainly refers to tablets and is prepared from the following components in parts by weight: 1100 to 1300 parts of common andrographis herb, 900 to 1100 parts of Chinese knotweed herb, 700 to 900 parts of wikstroemia indica, 900 to 1100 parts of jasminum elongatum, 300 to 360 parts of pomegranate bark, 300 to 360 parts of plantain herb and 640 to 700 parts of ilex rotunda thunb. The anti-inflammation and detoxification preparation provided by the invention has remarkable curative effects on phlegm-heat cough and asthma, acute and chronic tonsillitis, sphagitis, pulmonitis, stomachache, diarrhea, vomit, acute gastroenteritis and acute bacillary dysentery. The invention also provides a preparation method of the anti-inflammation and detoxification preparation. The tablets prepared by using the preparation method are high in purity of active ingredients and prone to mechanical and automatic production. The invention also provides a quality control method for the anti-inflammation and detoxification preparation. The anti-inflammation and detoxification preparation is a pure traditional Chinese medicine preparation, is accurate in dosage, stable in product quality, convenient to take, safe and free of toxic and side effects and has relatively strong competitive power in terms of product cost and brand effect on the market; the cost is reduced and the product quality is ensured.
Vincristine Sulfate Injection, USP when diluted with 0.9% Sodium Chloride Injection in concentrations from 0.0015 mg/mL to 0.08 mg/mL is stable for up to 24 hours when protected from light or 8 hours under normal light at 25°C.

Caution: It is extremely important that the intravenous needle or catheter be properly positioned before any vincristine is injected. Leakage into surrounding tissue during intravenous administration of Vincristine Sulfate Injection, USP may cause considerable irritation. If extravasation occurs, the injection should be discontinued immediately and any remaining portion of the dose should then be introduced into another vein. Local injection of hyaluronidase and the application of moderate heat to the area of leakage will help disperse the drug and may minimize discomfort and the possibility of cellulitis.

Vincristine Sulfate Injection, USP must be administered via an intact, free–flowing intravenous needle or catheter. Care should be taken that there is no leakage or swelling occurring during administration (see boxed WARNINGS).

The diluted Vincristine Sulfate Injection may be infused via a flexible plastic container directly into an intravenous catheter/needle or into a running intravenous infusion (see Drug Interactions below).
Use ZYCLARA, 2.5% or 3.75% for the treatment of AK. Apply a thin layer of ZYCLARA once daily before bedtime to the area with AK (either entire face or balding scalp) for two 2-week treatment cycles separated by a 2-week no-treatment period. Rub in until the cream is no longer visible. Apply up to 0.5 grams (two packets or two full actuations of the pump) of ZYCLARA at each application. Leave ZYCLARA on the skin for approximately 8 hours and then remove with mild soap and water.

For local skin reactions, a dosage interruption of several days may be taken if required based on the patient’s discomfort or severity of the local skin reaction [see Warnings and Precautions (5.1)]. Do not extend either 2-week treatment cycle due to missed doses or rest periods .Assess response to treatment after resolution of local skin reactions. 

A transient increase in lesion counts may be observed during treatment; however, continue dosing as prescribed. Continue treatment for the full treatment course even if all AK appear to be gone.
An esophageal motility disorder is when muscular contractions become discoordinated or weak and interfere with movement of food down the esophagus. Some esophageal motility disorders persist long enough to cause severe problems requiring surgical intervention. Achalasia, one subtype of esophageal motility disorder that is a rare disease, can be defined by the esophageal sphincter and muscle unable to relax or dilate. Left untreated, symptoms such as difficulty swallowing, regurgitation, heartburn, and chest pain may easily turn into complications such as severe weight loss, malnutrition, coughing, pulmonary infection, pneumonia, and perforation of the esophagus. Diagnosis of esophageal achalasia can be determined by esophageal manometry and/or barium swallow esophagram. Treatment for achalasia includes balloon dilation, botulinum toxin injection and surgical intervention. Balloon dilation is performed by inserting a balloon through the esophageal sphincter, inflating the balloon, disrupting the esophageal muscle. Botox has also been known to successfully relax spastic muscle contractions of achalasia through direct injection into the esophageal muscle. Unfortunately, each alternative to surgical treatment often requires repeated administration to improve the symptoms of achalasia. Traditional treatment of achalasia has included open abdominal or thoracic surgical procedures to cut valve muscles between the esophagus and stomach (Heller Myotomy). Laparoscopic multi-port Heller myotomies have become the preferred approach, requiring 4 smaller abdominal incisions for placement of laparoscope equipment. Results of this laparoscopic technique have proven that although 2/3 of the patient population was successfully treated, a subset of this group still need repeat surgical procedures or balloon dilation. Recently, single-incision laparoscopic Heller myotomies have produced favorable results, with a single umbilical incision preferential to multiple-incision laparoscopy. We propose adoption of a new, incisionless approach to performing a Heller myotomy for the surgical treatment of achalasia. The method, the Peroral Endoscopic Myotomy (POEM) is expected to provide a less-invasive treatment for esophageal achalasia, ideally providing similar if not better outcomes as the Heller myotomy and can be adopted safely and effectively at Penn Medicine.
A composition comprises a low glycaemic index sugar and one or more flavonoid. The composition may be used as a carbohydrate substitute, in particular as a replacement for digestible starch and/or sucrose. The low glycaemic index sugar may be fructose, mannose or lyxose. Compositions of this type are particularly useful as a sweetener, in the manufacture of foods and beverages, or in the manufacture of medicaments where the compositions are a healthier and therapeutic alternative to sucrose and/or digestible starch. The composition can be used to lower glycosylation reactions in the body and are particularly useful for the therapeutic prophylactic treatment of diabetes. The composition may also contain prebiotics, vitamins and minerals. If the composition is to be used as a starch replacement, it advantageously contains a prebiotic, such as polydextrose, and a non-digestible fibre, such as cellulose.
Subjects in this arm will complete anaerobic exercise at home and at OHSU for the study. Subjects will use a Dexcom G6 CGM.
PURPOSE: To obtain the subject pharmaceutical agent composed of a soft gelatin capsule containing ibuprofen and codeine in a state partially dissolved and suspended in a polyoxyethylene-polyoxypropylene-diol and effective especially for mitigating the tumor pain and the postoperative pain. CONSTITUTION: This soft gelatin capsule contains 30-50 pts.wt. of ibuprofen and 1.5-4 pts.wt. of codeine in a state partially dissolved and partially suspended in 68.5-46 pts.wt. of a polyoxyethylene-polyoxypropylene-diol or in a mixture containing 30-76 pts.wt. of a polyoxyethylene-polyoxypropylene-diol, polyethylene glycol or polypropylene glycol and 7-40 pts.wt. of a physiologically compatible surfactant. The surfactant is e.g. a polyoxyethylene-glycerol-trihydroxystearate or a polyoxyethylene-(12-18C)aliphatic alcohol ether.
The invention relates to medicinal wine, and discloses a preparation method of external medicinal wine. The method comprises the following steps: soaking bark of croton tiglium and bark of yellow fruit tree in first wine, soaking bark of phoebe zhennan in second wine, mixing the first wine and the second wine with borneol. The external medicinal wine is prepared by adopting the bark of croton tiglium, the bark of yellow fruit tree and the bark of phoebe zhennan with pain relieving functions, and is researched on the basis. In addition, the preparation method is simple to operate, environment-friendly, economical, efficient and non-toxic, and has a wide application prospect. At present patients need to buy different medicines for different diseases, and each medicine only needs to be taken for a small amount, most of the medicines are stored at home until expiration, thus money is wasted. The external medicinal wine can be used for curing headache, migraine, toothache, pain of cervical vertebra, scapulohumeral periarthritis, backache, nephralgia, hyperostosis, rheumatalgia, pain of muscles and bones, flesh pain, dermatodynia, injury pain and scald, and thus the problems are solved.
Mulligan exercise protocol will be applied to the participants in this group. It will be applied to the participants for 4 weeks and 5 days a week for 30 minutes. The exercise program will be performed by the patient under the supervision of a physiotherapist.
No intervention was given to this group of participants. They were asked to rest and wait for 15 minutes, then post-test was performed.
Cerebral Palsy (CP) defined as a group of permanent impairments that is originating from non-progressive disorders that develop in the immature brain. CP leads activity limitations of movement and posture development.The first 20 years of life is characterized by rapid growth and specific changes in physical, social, and psychological development. Social participation and independence of children and youth are related to the changes in this period. Participation can be identified as being involved in life situations and it reflects the social aspect of functionality. The problems which can be come across in life situations are identified as participation limitation. In the past, the impairment seen in child was concentrated and child was the passive receptor of treatment. Today, this view is changed and child is the active participant of the treatment of disability. The aim of treatment is identified as increasing the quality of life by supporting the activity and participation according to the priorities of the child and the parent.

In literature, no adequate study has investigated the functional inadequacy, activity and participation of children with CP; this project has been planned in order to specify the importance in rehabilitation interventions more detailed. This project aims to specify whether the functional levels correspond to the activity and participation limitations of children with CP living in Ankara city center and determine the effects of their functional status on activity, participation and quality of life. This investigation will be pioneer in indicating the activity and participation limitations of children with CP. According to the results, these limitations will be overcome and the quality of life of children with CP will be increased. The CP follow-up database in Ankara will be specified so their physical activity and participation levels will be followed periodically and CP profile will be determined in Ankara. Moreover, the results of this study will be shared with the Ministry of National Education, the Ministry of Family and Social Policies, and the Ministry of Health and this will bring a different viewpoint to the community-based rehabilitation services in Turkey. Furthermore, this study will be expected to motivate countrywide investigations.

In the project, Gross Motor Function Classification System (GMFCS) for the severity of the disability of people with CP, The Measure of Processes of Care (MPOC) for their care process, the Pediatric Outcomes Date Collection (PODCI) Instrument and Pediatric Quality of Life Questionnaire and The Child Health Quality (CHQ PF-50) for their health-related quality of life, the Manual Ability Classification System (MACS) for the manual abilities and the Communication Function Classification System (CFCS) for the communication skill and the Life Habits Questionnaire (LIFE-H) for the participation level and Impact on Family Scale (IPFAM) for family impact will be used and the outcomes will be analyzed by adequate statistical methods. It is intended to be discussed the findings of the project in national and international platforms.
Doxycycline hyclate is a broad-spectrum antibiotic synthetically derived from oxytetracycline. The chemical designation is 4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacene-carboxamide monohydrochloride, compound with ethyl alcohol (2:1), monohydrate. Doxycycline is a light-yellow crystalline powder. Doxycycline Hyclate is soluble in water.

Doxycycline has a high degree of lipoid solubility and a low affinity for calcium binding. It is highly stable in normal human serum. Doxycycline will not degrade into an epianhydro form.

The structural formula is as follows:

Each tablet for oral administration contains doxycycline hyclate equivalent to 100 mg of doxycycline (anhydrous). Inactive ingredients are: Colloidal Silicon Dioxide, Corn Starch, Croscarmellose Sodium, Docusate Sodium, Magnesium Stearate, and Microcrystalline Cellulose. Film Coating and Polishing contains: FD&C Blue No. 2, FD&C Yellow No. 6, Hydroxypropyl Methylcellulose, Polyethylene Glycol, and Titanium Dioxide.
Pinctada fucata meat is the main by-product of the pearl harvesting industry. It is rich in nutrition, containing a lot of protein and peptides, and holds significant value for both medicine and food. In this study, a new active protein was discovered and expressed heterogeneously through bioinformatics analysis. It was then identified using Western blot, molecular weight, and mass spectrometry. The antibacterial activity, hemolysis activity, antioxidant activity, and Angiotensin-Converting Enzyme II (ACE2) inhibitory activity were investigated. An unknown functional protein was screened through the Uniprot protein database, and its primary structure did not resemble existing proteins. It was an α-helical cationic polypeptide we named PFAP-1. The codon-optimized full-length PFAP-1 gene was synthesized and inserted into the prokaryotic expression vector pET-30a. The induced expression conditions were determined with a final isopropyl-β-d-thiogalactoside (IPTG) concentration of 0.2 mM, an induction temperature of 15 °C, and an induction time of 16 h. The recombinant PFAP-1 protein, with low endotoxin and sterility, was successfully prepared. The recombinant PFAP-1 protein exhibited strong antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) in vitro, and the diameter of the inhibition zone was 15.99 ± 0.02 mm. Its minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were 37.5 μg/mL and 150 μg/mL, respectively, and its hemolytic activity was low (11.21%) at the bactericidal concentration. The recombinant PFAP-1 protein significantly inhibited the formation of MRSA biofilm and eradicated MRSA biofilm. It also demonstrated potent 1,1-diphenyl-2-picryl-hydrazyl radical (DPPH) scavenging activity with a half-maximal inhibitory concentration (IC50) of 40.83 μg/mL. The IC50 of ACE2 inhibition was 5.66 μg/mL. Molecular docking results revealed that the optimal docking fraction of PFAP-1 protein and ACE2 protein was -267.78 kcal/mol, with a confidence level of 0.913. The stable binding complex was primarily formed through nine groups of hydrogen bonds, three groups of salt bridges, and numerous hydrophobic interactions. In conclusion, recombinant PFAP-1 can serve as a promising active protein in food, cosmetics, or medicine.
Matching placebo will be administered by IV infusion at Baseline (Day 1) of Part 2. PET/CT scan will be done on Weeks 2, 4 and 6. Participants will receive FDG as part of the PET/CT procedures and will provide sputum/blood samples.
RATIONALE & OBJECTIVE: End-stage kidney disease (ESKD) negatively affects patients' physical, emotional, and social functioning. Furthermore, adjustment to dialysis require substantial lifestyle changes that may further impact on patients physical and emotional well-being. However, the relationship between Health-Related Quality of life impairment with future adverse outcomes in dialysis is not well characterized. Our study aims to investigate the relationship between Health-Related Quality of Life (HRQoL) and patients' survival and hospitalization rates within a large European dialysis network.
METHODS: A historical cohort study was conducted to evaluate association of HRQoL with hospitalization and mortality rates over a 12-month follow-up period. Patients responded to a self-administered survey as part of a Continuous Quality Improvement Program implemented in clinics affiliated with the Spanish FMC-Nephrocare organization. Health-Related Quality of Life (HRQoL) was measured with the KDQOL-36. Potential confounders included socio-demographic characteristics, comorbidities, biochemical parameters, dialysis treatment. We used Cox's Proportional Hazard regression to assess the hazard of death and Logistic Regression to assess the likelihood of hospital admissions during 12-month follow-up period.
RESULTS: A total of 2280 (51.5%) completed the self-administrated survey, and 1838 patients met the inclusion/exclusion criteria of the study. Higher HRQoL scores were associated with significantly lower mortality and hospitalization risk. Risk estimates were robust to adjustment for potential confounders.
CONCLUSIONS: Several dimensions of HRQoL are associated with patient-centered outcomes (i.e., mortality and hospitalizations at 1 year). Patient-Reported Outcomes contribute unique pieces of information characterizing patients' health. Residual confounding cannot be fully ruled out; moreover, the high attrition rate could result in selection bias, which may limit the generalizability of the findings to a broader population.
The invention relates to a traditional Chinese medicine composition for treating pulmonary tuberculosis and an acupoint combined acupuncture application. The composition is characterized in that the composition is prepared from the following selected traditional Chinese medicinal raw materials in parts by weight: 50g of selfheal, 10g of artemisia apiacea and 5g of turtle shells. After combining the medicines, the composition has the functions of clearing away heat and toxic materials, inhibiting bacteria, resisting viruses, adjusting immunity, promoting blood circulation to remove blood stasis, moistening lung and diminishing swelling, clearing heat and expelling damp and the like. In the medicine-taking period of a patient, and acupoints such as fei shu, zhichuai, dazhui, kongzui, zhongchuai and the like are combined with acupuncture stimulation to form a physical stimulation acupuncture point therapy, and the composition and the therapy are combined to achieve the optimal effect of treating pulmonary tuberculosis. The therapy is coordinated with the effect to treat both symptoms and root causes, so that the immune function of the body is improved and protected. The curative effect is remarkable, the method is simple, the treatment course is short, the medication is simple and feasible, the curative effect is fast, the effect is good and the cost is low.
PURPOSE:To provide the subject hepatopathy inhibitor containing cystathionine and taurine as the active components and showing a remarkable effect especially for hepatopathy due to acetoaminophene. CONSTITUTION:Cystathionine, i.e., a precursor of cysteine and taurine, i.e., a metabolite of cysteine are blended and in addition a conventional vehicle, a binder, a diluent, etc., are added thereto. The resultant mixture is prepared by the conventional method to obtain the objective inhibitor. The inhibitor can be prepared into such a form as powder, granule, tablet, capsule or injection. Cystathionine is blended in molar ratio of >=0.3 based on 1 mole taurine. The dosage for an adult is preferably 10mg-10g per day in case of oral administration. The hepatopathy inhibition action of cystathionine is improved and the same activity can be shown even by administration of a reduced amount of expensive cystathionine.
A vaping cartridge is disclosed herein. The vaping cartridge comprises a base portion. A container portion is connected to the base portion and extends from the base portion. The container portion is configured to receive and contain a vaping liquid therewithin. A first intake opening is configured on the container portion for receiving the vaping liquid therewithin. A second intake opening configured on the container portion for allowing air to be permitted within the container portion. A mouthpiece is configured at a free end of the container portion. At least one article is disposed within the container portion immersed within the vaping liquid.
A system for providing a reliable and redundant enterprise management solution includes an appliance disposed at a healthcare facility and a pair device disposed at a remote facility. The appliance includes first processing circuitry, a first virtualization manager and a first synchronizer. The first processing circuitry is configured to enable execution of a plurality of applications. The first virtualization manager is configured to virtualize at least storage components and an execution environment for at least some of the applications. The pair device includes second processing circuitry, a second virtualization manager and a second synchronizer. The second processing circuitry provides redundancy for the first processing circuitry. The second virtualization manager is configured to provide redundancy with respect to the virtualized storage components and execution environment. The second synchronizer is configured to communicate with the first synchronizer to enable shifting of operations with respect to one of the applications being executed between the appliance and the pair device. A corresponding method and apparatus are also provided.